KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Average (2016 - 2026)

Gilead Sciences filings provide 17 years of Equity Average readings, the most recent being $22.0 billion for Q4 2025.

  • On a quarterly basis, Equity Average rose 16.85% to $22.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $22.0 billion, a 16.85% increase, with the full-year FY2025 number at $21.0 billion, changed 0.31% from a year prior.
  • Equity Average hit $22.0 billion in Q4 2025 for Gilead Sciences, up from $20.5 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $22.5 billion in Q4 2023 to a low of $17.8 billion in Q2 2024.
  • Median Equity Average over the past 5 years was $20.5 billion (2022), compared with a mean of $20.2 billion.
  • The widest YoY moves for Equity Average: up 19.17% in 2021, down 17.05% in 2021.
  • Gilead Sciences' Equity Average stood at $21.3 billion in 2021, then dropped by 0.63% to $21.1 billion in 2022, then increased by 6.45% to $22.5 billion in 2023, then dropped by 16.16% to $18.9 billion in 2024, then grew by 16.85% to $22.0 billion in 2025.
  • The last three reported values for Equity Average were $22.0 billion (Q4 2025), $20.5 billion (Q3 2025), and $19.3 billion (Q2 2025) per Business Quant data.